Highlights
1 patentProfile claimed by owner
About
Medicines for Life-threatening CNS Diseases
NeuroRX is a specialized CNS biopharma company, resolutely focused on meeting very high unmet medical needs for those with severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD).
The company growing pipeline is powered by its proprietary, dual-targeted mechanism of action, which safely modulates the NMDA and 5HT2A receptors. Its mission is to bring hope to people with life-threatening diseases through breakthrough science.
Identity
| Name | NRx Pharmaceuticals |
|---|---|
| Slug | nrx-pharmaceuticals |
| Type / kind | startup |
| Crunchbase ID | neurorx |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgIHe2o0KDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on May, 2021<br> |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Haifa |
| HQ address | Andrei Sakharov St 9, Haifa, Israel |
Web & social
| Website | https://www.nrxpharma.com/ |
|---|---|
| Careers page | https://www.nrxpharma.com/careers |
| https://www.linkedin.com/company/10024731 | |
| Twitter / X | https://twitter.com/NeuroRxPharma |
| https://www.facebook.com/NRxPharma |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business models
B2B
Tags
mental-healthpsychiatrypharmaceuticalsschizophreniachronic-pain
Funding
| Total raised | $176.2M |
|---|---|
| Current stage | Public |
| Market cap | $80.2M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}